Literature DB >> 27837105

The Analysis of CD83 Expression on Human Immune Cells Identifies a Unique CD83+-Activated T Cell Population.

Xinsheng Ju1, Pablo A Silveira1,2, Wei-Hsun Hsu1,2, Zehra Elgundi1, Renz Alingcastre1, Nirupama D Verma1, Phillip D Fromm1,2, Jennifer L Hsu1,3, Christian Bryant1,3, Ziduo Li1,2, Fiona Kupresanin1, Tsun-Ho Lo1,2, Candice Clarke4, Kenneth Lee2,4, Helen McGuire5, Barbara Fazekas de St Groth5, Stephen R Larsen2,3, John Gibson2,3, Kenneth F Bradstock1,2, Georgina J Clark1,2, Derek N J Hart6,2.   

Abstract

CD83 is a member of the Ig gene superfamily, first identified in activated lymphocytes. Since then, CD83 has become an important marker for defining activated human dendritic cells (DC). Several potential CD83 mRNA isoforms have been described, including a soluble form detected in human serum, which may have an immunosuppressive function. To further understand the biology of CD83, we examined its expression in different human immune cell types before and after activation using a panel of mouse and human anti-human CD83 mAb. The mouse anti-human CD83 mAbs, HB15a and HB15e, and the human anti-human CD83 mAb, 3C12C, were selected to examine cytoplasmic and surface CD83 expression, based on their different binding characteristics. Glycosylation of CD83, the CD83 mRNA isoforms, and soluble CD83 released differed among blood DC, monocytes, and monocyte-derived DC, and other immune cell types. A small T cell population expressing surface CD83 was identified upon T cell stimulation and during allogeneic MLR. This subpopulation appeared specifically during viral Ag challenge. We did not observe human CD83 on unstimulated human natural regulatory T cells (Treg), in contrast to reports describing expression of CD83 on mouse Treg. CD83 expression was increased on CD4+, CD8+ T, and Treg cells in association with clinical acute graft-versus-host disease in allogeneic hematopoietic cell transplant recipients. The differential expression and function of CD83 on human immune cells reveal potential new roles for this molecule as a target of therapeutic manipulation in transplantation, inflammation, and autoimmune diseases.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27837105     DOI: 10.4049/jimmunol.1600339

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Putative loss of CD83 immunosuppressive activity in long-standing complication-free juvenile diabetic patients during disease progression.

Authors:  Ulana Juhas; Monika Ryba-Stanisławowska; Urszula Ławrynowicz; Małgorzata Myśliwiec; Jolanta Myśliwska
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

2.  The Nucleocapsid Protein and Nonstructural Protein 10 of Highly Pathogenic Porcine Reproductive and Respiratory Syndrome Virus Enhance CD83 Production via NF-κB and Sp1 Signaling Pathways.

Authors:  Xi Chen; Qiaoya Zhang; Juan Bai; Yongxiang Zhao; Xianwei Wang; Haiyan Wang; Ping Jiang
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

3.  Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody.

Authors:  Ziduo Li; Edward Abadir; Kenneth Lee; Candice Clarke; Christian E Bryant; Wendy Cooper; Geoffrey Pietersz; James Favaloro; Pablo A Silveira; Derek Nj Hart; Xinsheng Ju; Georgina J Clark
Journal:  Clin Transl Immunology       Date:  2020-07-15

4.  Epithelial cell-derived CD83 restores immune tolerance in the airway mucosa by inducing regulatory T-cell differentiation.

Authors:  Li-Hua Mo; Xiang-Qian Luo; Gui Yang; Jiang-Qi Liu; Li-Teng Yang; Zhi-Qiang Liu; Shuai Wang; Da-Bo Liu; Zhi-Gang Liu; Ping-Chang Yang
Journal:  Immunology       Date:  2021-02-28       Impact factor: 7.215

5.  CD83 is a new potential biomarker and therapeutic target for Hodgkin lymphoma.

Authors:  Ziduo Li; Xinsheng Ju; Kenneth Lee; Candice Clarke; Jennifer L Hsu; Edward Abadir; Christian E Bryant; Suzanne Pears; Neroli Sunderland; Scott Heffernan; Annemarie Hennessy; Tsun-Ho Lo; Geoffrey A Pietersz; Fiona Kupresanin; Phillip D Fromm; Pablo A Silveira; Con Tsonis; Wendy A Cooper; Ilona Cunningham; Christina Brown; Georgina J Clark; Derek N J Hart
Journal:  Haematologica       Date:  2018-01-19       Impact factor: 9.941

6.  Linking Cell Dynamics With Gene Coexpression Networks to Characterize Key Events in Chronic Virus Infections.

Authors:  Mireia Pedragosa; Graciela Riera; Valentina Casella; Anna Esteve-Codina; Yael Steuerman; Celina Seth; Gennady Bocharov; Simon Heath; Irit Gat-Viks; Jordi Argilaguet; Andreas Meyerhans
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

Review 7.  CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.

Authors:  Ziduo Li; Xinsheng Ju; Pablo A Silveira; Edward Abadir; Wei-Hsun Hsu; Derek N J Hart; Georgina J Clark
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

8.  Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.

Authors:  Bishwas Shrestha; Kelly Walton; Jordan Reff; Elizabeth M Sagatys; Nhan Tu; Justin Boucher; Gongbo Li; Tayyebb Ghafoor; Martin Felices; Jeffrey S Miller; Joseph Pidala; Bruce R Blazar; Claudio Anasetti; Brian C Betts; Marco L Davila
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

9.  Interactions between dendritic cells and T lymphocytes in pathogenesis of nasal polyps.

Authors:  Xinsheng Lin; Xiayan Zhuang; Chuangwei Li; Xin Wang
Journal:  Exp Ther Med       Date:  2018-05-03       Impact factor: 2.447

10.  Inhibition of CD83 Alleviates Systemic Inflammation in Herpes Simplex Virus Type 1-Induced Behçet's Disease Model Mouse.

Authors:  S M Shamsul Islam; Hae-Ok Byun; Bunsoon Choi; Seonghyang Sohn
Journal:  Mediators Inflamm       Date:  2019-09-09       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.